聚桂醇瘤内注射硬化治疗肝血管瘤的临床疗效

发布时间：2018-03-31 06:15

本文选题：肝血管瘤　切入点：聚桂醇　出处：《中国介入影像与治疗学》2015年01期

【摘要】：目的探讨超声引导下经皮经肝穿刺聚桂醇瘤内注射硬化治疗肝血管瘤的安全性及有效性。方法将56例肝血管瘤患者,随机分为对照组29例(34个瘤灶),行平阳霉素瘤内注射硬化治疗;研究组27例(33个瘤灶),行聚桂醇瘤内注射硬化治疗。观察治疗前和治疗后3、6个月时患者临床症状、瘤体大小变化及不良反应。结果对56例患者均顺利实施硬化治疗,手术成功率100%。对照组与研究组患者治疗前及治疗后3、6个月血管瘤平均最大直径的差异无统计学意义(P均0.05);治疗3、6个月的有效率分别为58.82%、70.59%和54.54%、66.67%,差异均无统计学意义。两组患者治疗中及治疗后均未发生严重并发症。结论超声引导下经皮穿刺瘤内注射聚桂醇硬化治疗肝血管瘤安全有效。
[Abstract]:Objective to investigate the safety and efficacy of percutaneous transhepatic injection sclerosing in the treatment of hepatic hemangioma under the guidance of ultrasound. Twenty-nine patients were randomly divided into control group (34 lesions, treated with pingyangmycin intratumoral injection sclerotherapy) and study group (33 tumor foci, treated with intratumoral injection sclerosing of polycinnamol). Clinical symptoms were observed before treatment and 3months and 6 months after treatment. Results 56 patients were treated successfully with sclerotherapy. There was no significant difference in mean maximum diameter of hemangioma between the control group and the study group before and after 3 and 6 months of treatment, and the effective rate of the treatment for 3 and 6 months was 58.820.59% and 54.54%, respectively. There was no significant difference in the mean maximum diameter of hemangioma between the control group and the study group, and there was no significant difference in the mean maximum diameter of hemangioma between the control group and the study group. There were no serious complications in both groups. Conclusion Ultrasound-guided percutaneous intratumoral injection of polycinnamol in the treatment of hepatic hemangioma is safe and effective.
【作者单位】：浙江大学医学院附属第一医院超声影像科;
【分类号】：R735.7;R445.1

【参考文献】